ACP-105 — Safety, Research, Risks & Legal Status

Not medical advice. ACP-105 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	ACP105
Category	SARM
development_era	Early 2000s preclinical program
tissue_selectivity	Intended bone and muscle preference; mechanism not fully elucidated
US legal status	Not FDA-approved for human use. Sold as a research chemical only. WADA-banned. No approved pharmaceutical form.

What is ACP-105?

Nonsteroidal selective androgen receptor modulator (SARM) developed for musculoskeletal conditions. Synthetic compound designed to preferentially activate androgen receptors in bone and muscle.

How it works

Selective androgen receptor agonist with reported affinity for muscle and bone tissue. Mechanism of tissue selectivity poorly understood; proposed to involve differential co-regulator expression.

Background & history

Developed in early 2000s as part of academic SARM discovery program. Preclinical work discontinued; never advanced to investigational drug phase due to competitive landscape.

What the research says

Preclinical and early animal evidence only. No published human Phase II/III trials. Animal studies report anabolic effects on bone and muscle. Expected androgen receptor-driven suppression of testosterone. Research is limited and older in publication timeline.

Reported effects

Reported anabolic bone effects in animal studies
Studied for muscle growth potential
Expected androgen receptor selectivity
Likely suppresses endogenous testosterone
Limited research depth compared to later SARMs

Dosing & administration (informational)

Early animal studies used escalating dose protocols to assess efficacy and tolerability thresholds. Human equivalent doses completely unknown.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No human safety data; major evidence gap
Testosterone suppression expected
Cardiovascular and liver impact unknown in humans
WADA-banned; prohibited in sport
Unregulated vendor sourcing means high contamination risk
Older compound with less modern safety scrutiny

Drug & supplement interactions

Additive suppression expected with concurrent androgens
Unknown modulation of cytochrome P450 enzyme activity
May interact with sex hormone-binding globulin systems
Potential crosstalk with estrogen signaling pathways

Who should avoid it

Concurrent use with anabolic steroids or other SARMs
In individuals with cardiovascular or liver disease
In those with pre-existing testicular atrophy or sexual dysfunction
In competitive sport environments or drug-tested settings

How it is commonly combined

No validated human combinations; multi-compound use dramatically increases toxicological risk and organ-damage potential.

Legal & regulatory. Not FDA-approved for human use. Sold as a research chemical only. WADA-banned. No approved pharmaceutical form.

Quality & harm reduction

R
e
q
u
e
s
t
i
n
d
e
p
e
n
d
e
n
t
t
h
i
r
d
-
p
a
r
t
y
C
O
A
v
e
r
i
f
y
i
n
g
p
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
.
C
h
e
c
k
f
o
r
s
o
l
v
e
n
t
r
e
s
i
d
u
e
s
a
n
d
m
i
c
r
o
b
i
a
l
c
o
n
t
a
m
i
n
a
t
i
o
n
;
n
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
a
s
s
u
r
a
n
c
e
t
y
p
i
c
a
l
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is ACP-105 ever used as medicine?

No. Never approved or used clinically. Research chemical only, unregulated.

Why is it less talked about than other SARMs?

Older compound; newer SARMs (RAD, LGD) received more research funding and attention.

What happens if you use it?

Unknown in humans. Testosterone suppression expected, but organ impact, duration of effects, and long-term safety are unvalidated.

How do you know if you got real ACP-105?

Only a third-party lab test can confirm identity and purity; most vendors do not provide this.

What makes it riskier than newer SARMs?

Less modern research scrutiny; preclinical work is dated and limited in scope.

References & further reading

WADA Prohibited List (androgen receptor agonists)
FDA guidance on development of tissue-selective androgen receptor modulators
PubMed historical preclinical data on ACP-105 bone and muscle selectivity